ArticleNeurosurgical review2025
Repeated recurrence after endovascular treatment for cerebral aneurysms: predictive clinical factors and optimal therapeutic management.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of angiotensin-converting-enzyme inhibitors in endovascular treatment of intracranial aneurysms.Neuroradiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite significant advances in endovascular treatment (EVT) of cerebral aneurysms, post-treatment recurrence necessitating multiple retreatments remains a severe concern. Herein, we investigated the clinical characteristics of aneurysms necessitating multiple retreatments after EVT (refractory aneurysms: R-ANs) and explored appropriate management strategies. This retrospective cohort study enrolled 1,045 aneurysms initially treated with EVT between 2016 and 2022. R-ANs were defined as cases requiring two or more retreatment sessions due to repeated recurrence or regrowth. Clinical data were retrospectively reviewed, and predictive factors were identified. Furthermore, the treatments performed and clinical outcomes were investigated. Of 1,045 aneurysms, 101 (9.7%) exhibited recurrence or regrowth requiring retreatment. Among these, 23 aneurysms (2.2%) requiring two or more retreatment sessions, which were classified as R-ANs. As for the predictive factors of R-AN development, large size (> 10 mm), and circumferential aneurysmal wall enhancement on vessel wall imaging (VWI) were identified as relevant and independent predictive factors, with odds ratios of 3.92 (95% CI, 1.36- 11.62), 8.02 (95% CI, 2.02- 53.6), respectively. In terms of therapeutic outcomes, repeat EVT sessions provided favorable long-term clinical outcomes (aneurysm stabilization, 85.0%; favorable occlusion, 65.0%) and low periprocedural complication rates (2.6%). This study identified the relevant predictive factors for R-AN development, suggesting that careful follow-up is essential in patients with these factors. Furthermore, repeated EVT sessions appears to be a safe and efficient treatment strategy for such challenging cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.